3 unchanged sentences
EXHIBIT INDEX
−Removed: Amended and Restated Bylaws of Iovance Biotherapeutics, Inc.
−Removed: (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on May 27, 2020).
−Removed: Iovance Biotherapeutics, Inc.
−Removed: 2020 Employee Stock Purchase Plan (incorporated herein by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K filed with the Commission on June 9, 2020).
−Removed: Iovance Biotherapeutics, Inc.
−Removed: 2018 Equity Incentive Plan, as amended (incorporated herein by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K filed with the Commission on June 9, 2020).
−Removed: Second Amendment to the Lease Agreement, effective as of June 30, 2020, between Iovance Biotherapeutics, Inc.
−Removed: and 300 Rouse Boulevard, LLC.
Severance Agreement and General Release, effective July 8, 2020, between Iovance Biotherapeutics, Inc.
−Removed: and Timothy Morris.
+Added: and Timothy Morris (incorporated herein by reference to Exhibit 10.4 to the Registrants Quarterly Report on Form 10-Q filed with the Commission on August 6, 2020).
Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer.
3 unchanged sentences
The following financial information from the Quarterly Report on Form 10-Q of Iovance Biotherapeutics, Inc.
−Removed: for the quarter ended June 30, 2020, formatted in XBRL (eXtensible Business Reporting Language):
−Removed: (1) Condensed Consolidated Balance Sheets as of June 30, 2020 and December 31, 2019;
−Removed: (2) Condensed Consolidated Statements of Operations for the three and six months ended June 30, 2020 and 2019;
−Removed: (3) Condensed Consolidated Statements of Comprehensive Loss for the three and six months ended June 30, 2020 and 2019;
−Removed: (4) Condensed Consolidated Statements of Stockholders’ Equity as of June 30, 2020 and December 31, 2019;
−Removed: (5) Condensed Consolidated Statements of Cash Flows for the three months ended June 30, 2020 and 2019;
+Added: for the quarter ended September 30, 2020, formatted in iXBRL (Inline eXtensible Business Reporting Language):
+Added: (1) Condensed Consolidated Balance Sheets as of September 30, 2020 and December 31, 2019;
+Added: (2) Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2020 and 2019;
+Added: (3) Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2020 and 2019;
+Added: (4) Condensed Consolidated Statements of Stockholders’ Equity as of September 30, 2020 and December 31, 2019;
+Added: (5) Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2020 and 2019;
and (6) Notes to Condensed Consolidated Financial Statements.
+Added: Cover Page Interactive Data File – the cover page interactive date file does not appear in the Interactive Date File because its XBRL tags are embedded within the Inline XBRL document.
Certain portions of the Exhibit have been redacted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
3 unchanged sentences
Iovance Biotherapeutics, Inc.
−Removed: August 6, 2020
+Added: November 5, 2020
/s/ Maria Fardis, Ph.D., M.B.A.
1 unchanged sentence
Chief Executive Officer (Principal Executive Officer)
−Removed: August 6, 2020
+Added: November 5, 2020
/s/ Michael C.
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.